WHO ICTRP trial
Efficacy and safety of tislelizumab in combination with chemotherapeutic…
ChiCTR2400081493 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400081493 |
|---|---|
| Public title | Efficacy and safety of tislelizumab in combination with chemotherapeutic conversion therapy for stage III-N3 non-small cell lung cancer: a multi-center, single-arm, phase 2 trial |
| Scientific title | Efficacy and safety of tislelizumab in combination with chemotherapeutic conversion therapy for stage III-N3 non-small cell lung cancer: a multi-center, single-arm, phase 2 trial |
| Primary sponsor | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and PeKing Union Medical College |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Non-small cell lung cancer |
| Interventions | Experimental Group:tislelizumab in combination with chemotherapeutic conversion therapy |
| Registration date | Mar 4, 2024 |
| Target size | Experimental Group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: